STEPS Trial - Spheramine Safety and Efficacy Study

Bayer

Status and phase: Terminated; Phase 2

Conditions: Parkinson Disease

Treatments: Biological: Spheramine (BAY86-5280); Procedure: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00206687

305405 (Other Identifier)

91039

Details and patient eligibility

About

The purpose of the study is to explore the safety, tolerability and efficacy of Spheramine (cultured human retinal pigment epithelial cells on microcarriers) in Parkinson's Disease patients with advanced disease who have insufficient symptom control by optimum oral medication. Patients are randomized to receive Spheramine injections into both hemispheres or a sham surgical procedure in a ratio of 1:1. A three month pretreatment period must be completed prior to surgery. Time to endpoint is 24 months.

Full description

This study has previously been posted by Berlex, Inc. and Schering AG, Germany.Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors of the trial.

Enrollment: 71 patients

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced Parkinson's disease for at least 5 years
• Good response to L-dopa
• Age 30 to 70 years
• Optimum oral therapy

Exclusion criteria

• Tremor only
• Dementia
• Very severe dyskinesia
• Previous brain surgery including deep brain stimulation
• Malignant disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

71 participants in 2 patient groups

Arm 1

Experimental group

Treatment:

Biological: Spheramine (BAY86-5280)

Arm 2

Sham Comparator group

Treatment:

Procedure: Placebo